PT  - JOURNAL ARTICLE
AU  - Habibi, Danial
AU  - Teymoori, Farshad
AU  - Ebrahimi, Navid
AU  - Tehrani Fateh, Sahand
AU  - Najd-Hassan-Bonab, Leila
AU  - Saeidian, Amir Hossein
AU  - Soleymani Taloubaghi, Alireza
AU  - Asgarian, Sara
AU  - Hosseinpanah, Farhad
AU  - Hakonarson, Hakon
AU  - Azizi, Fereidoun
AU  - Hedayati, Mehdi
AU  - Daneshpour, Maryam Sadat
AU  - Akbarzadeh, Mahdi
AU  - Mansourian, Marjan
TI  - Causal effect of serum 25 hydroxyvitamin D concentration on cardioembolic stroke: Evidence from Two-sample Mendelian randomization
AID  - 10.1101/2023.10.11.23296798
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.11.23296798
4099  - http://medrxiv.org/content/early/2023/10/12/2023.10.11.23296798.short
4100  - http://medrxiv.org/content/early/2023/10/12/2023.10.11.23296798.full
AB  - Background/Aim The putative association between serum 25 hydroxyvitamin D concentration 25(OH)D and the risk of cardioembolic stroke (CES) has been examined in observational studies, which indicate controversial findings. We performed Mendelian randomization (MR) analysis to determine the causal relationship of serum 25(OH)D with the risk of CES.Method The summary statistics dataset on the genetic variants related to 25(OH)D was used from the published GWAS of European descent participants in the UK Biobank, including 417,580 subjects, yielding 143 independent loci in 112 1-Mb regions. GWAS summary data of CES was obtained from GIGASTROKE Consortium, which included European individuals (10,804 cases, 1,234,808 controls).Results Our results unveiled 99 SNPs contributing a causal relationship between 25(OH)D and CES using IVW [OR□=□0.82, 95% CI: 0.67-0.98, p□=□0.037]. Horizontal pleiotropy was not seen by the MR-Egger intercept-based test [MR-Egger intercept□=□0.001; p□=□0.792], suggesting an absence of horizontal pleiotropy. Cochrane’s Q value [Q=78.71, p-value□=□0.924], Rucker’s Q [Q=78.64, p-value=0.913], and I2=0.0% (95% CI: 0.0%, 24.6%) statistic suggested no heterogeneity in the connection between 25(OH)D and CES. This result remained consistent using different MR method and sensitivity analyses, including Maximum likelihood [OR=0.82, 95%CI: 0.67-0.98, p-value=0.036], Constrained maximum likelihood method [OR=0.76, 95%CI: 0.64-0.90, p-value=0.002], Debiased inverse-variance weighted method [OR=0.82, 95%CI: 0.68-0.99, p-value=0.002], MR-PRESSO [OR=0.82, 95%CI 0.77-0.87, p-value=0.022], RAPS [OR=0.82, 95%CI 0.67-0.98, p-value=0.038], MR-Lasso [OR=0.82, 95%CI 0.68-0.99, p-value=0.037].Conclusion Our MR analysis provides suggestive evidence that increased 25(OH)D levels may play a causally protective role in the development of cardioembolic stroke. Determining the role of 25(OH)D in stroke subtypes has important clinical and public health implications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The dataset employed in this study was obtained from the GWAS catalog (https://www.ebi.ac.uk/gwas/). for vitamin D measurement the study accession is GCST90000614 and for cardioembolic stroke the study accession is GCST90104541.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe original data used are publicly available at https://gwas.mrcieu.ac.uk/. The original contributions presented in the study are included in the article/Supplementary Material; The process of MR analyses and the results are publicly available through the following HTML link: https://akbarzadehms.github.io/VitDcardioembolicStrokeMR/